Page 358 - The Vasculitides, Volume 1: General Considerations and Systemic Vasculitis

332 Vanessa Quick and John Kirwan

[117] Fuchs M, Briel M, Daikeler T, et al. The impact of 18F-FDG PET on the management of
patients with suspected large vessel vasculitis. Eur. J. Nucl. Med. Mol. Imaging, 2012;
39:344-353.

[118] Besson FL, Parienti JJ, Bienvenu B, et al. Diagnostic performance of 18F-
fluorodeoxyglucose positron emission tomography in giant cell arteritis: a systematic
review and meta-analysis. Eur. J. Nucl. Med. Mol. Imaging, 2011; 38:1764-1772.

[119] Rudd JH, Myers KS, Bansilal S, et al. Atherosclerosis inflammation imaging with 18F-
FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods,
and recommendations. Journal of Nuclear Medicine, 2008; 49:871-878.

[120] Frost A, Eachus J, Sparrow J et al. Vision-related quality of life impairment in an
elderly UK population: associations with age, sex, social class and material deprivation.
Eye, 2001; 15:739-744.

[121] Graham E, Holland A, Avery A, et al. Prognosis in Giant Cell Arteritis. BMJ, 1981;
282:269-271.

[122] Hoffman GS, Cid MC, Hellmann DB, et al. Multicenter, Randomized, Double-Blind,
Placebo-Controlled Trial of Adjuvant Methotrexate Treatment for Giant Cell Arteritis.
Arthritis Rheum, 2002; 46:1309-1318.

[123] Jover JA, Hernandez-Garcia C, Morado IC, et al. Combined treatment of giant-cell
arteritis with methotrexate and prednisone-A randomized, double-blind, placebo-
controlled trial. Ann. Intern. Med., 2001; 134106-114.

[124] Martinez-Lado L, Calvino-Díaz C, Pineiro A, et al. Relapses and recurrences in giant
cell arteritis: a population-based study of patients with biopsy-proven disease from
northwestern Spain. Medicine, 2011; 90:186-193.

[125] Weyand CM, Fulbright JW, Hunder GG, et al: Treatment of giant cell arteritis:
interleukin-6 as a biological marker of disease activity. Arthritis Rheum., 2000;
43:1041-1048.

[126] Masson C. Therapautic approach to giant cell arteritis. Joint. Bone Spine, 2011; 79:219-
227.

[127] Kyle V, Cawston TE, Hazleman BL. Erythrocyte sedimentation rate and C reactive
protein in the assessment of polymyalgia rheumatica/giant cell arteritis on presentation
and during follow up. Ann. Rheum. Dis., 1989; 48:667-671.

[128] Hayreh SS, Zimmerman B. Management of giant cell arteritis: our 27-year clinical
study: new light on old controversies. Ophthalmologica, 2003; 217:239-259.

[129] Spiera RF, Spiera H. Therapy for Giant Cell Arteritis: Can We Do Better? Arthritis
Rheum., 2006; 54:3071-3074.

[130] Agard C, Espitia O, Neel A. Prognosis of giant cell arteritis. Presse Medicale, 2012;
41:966-974.

[131] Nuenninghoff DM, Hunder GG, Christianson TJ, et al. Mortality of Large-Artery
Complication (Aortic Aneurysm, Aortic Dissection, and/or Large-Artery Stenosis) in
Patients with Giant Cell Arteritis. A Population-Based Study Over 50 Years. Arthritis
Rheum., 2003; 48:3532-3537.

[132] Crosby RC, Wadsworth RC. Temporal arteritis – review of the literature and report of 5
additional cases. Arch .Med. Interna, 1948:81:431-464.

[133] Marie I, Proux A, Duhaut P, et al. Long-term follow-up of aortic involvement in giant
cell arteritis: a series of 48 patients. Medicine, 2009; 88:182-192.

Complimentary Contributor Copy